Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis.
Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
The Purdue research is published in the Journal of Medicinal Chemistry.
“The death toll from TB is particularly high because of drug-resistant strains,” said Zhong-Yin Zhang, distinguished professor and head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology and director of Purdue Institute for Drug Discovery. “These inhibitors are part of a promising new approach to developing TB therapeutic agents with novel targets and mechanisms of action to help save more lives.”
Current treatments for TB are mostly antibiotic-based solutions. A major problem is that a large number of patients fail to take the entire antibiotic regime, which can lead to drug-resistant strains.
“We developed a platform to target mPTPB for novel anti-TB agents that builds on technologies we pioneered to modulate abnormal protein tyrosine phosphatase activity for the treatment of diseases such as cancer, diabetes and autoimmune disorders,” Zhang said.
Zhang said these inhibitors’ properties also make them promising drug candidates. They possess lighter molecular weights, excellent metabolic stability and bioavailability to provide a starting point for further therapeutic development for use as TB treatments.
The innovators worked with the Purdue Research Foundation Office of Technology Commercialization to patent their technology.
The innovators and OTC are looking for partners to continue developing their technology. For more information on licensing and other opportunities, contact Joseph Kasper of OTC at [email protected] and mention track code 2020-ZHAN-68995.
Original Article: New inhibitors may offer novel approach to treating deadly tuberculosis
More from: Purdue University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Tuberculosis
- Tuberculosis outbreak: At least one dead, nine hospitalized, as health officials declare public health emergency California
A public health emergency has been declared in southern California after a tuberculosis outbreak left at least one person dead and nine hospitalized. Health officials said the outbreak was localized ...
- Long Beach declares public health emergency after deadly tuberculosis outbreak
City officials declared a public health emergency Thursday after a tuberculosis outbreak left one person dead and nine others hospitalized. Health officials said the outbreak stemmed from a group ...
- Long Beach health officials declare tuberculosis outbreak a public health emergency
Long Beach officials declared a public health emergency Thursday afternoon after one person died and nine others were hospitalized due to a tuberculosis outbreak in the city. The city’s chief health ...
- 1 person dead amid tuberculosis outbreak in Long Beach
A tuberculosis outbreak among residents of a single-room occupancy hotel in Long Beach has left one person dead and led to the hospitalizations of nine others, prompting the declaration of a public ...
- Tuberculosis outbreak at Long Beach hotel leads to one death, 9 hospitalized
A tuberculosis outbreak among residents of a single-room occupancy hotel in Long Beach has left one person dead and led to the hospitalizations of nine others.
Go deeper with Google Headlines on:
Tuberculosis
[google_news title=”” keyword=”tuberculosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Small molecule inhibitors
- Q1 2024 Kymera Therapeutics Inc Earnings Call
Biological differentiation of KC. two nine four from our stake to small molecule inhibitors was demonstrating through IL-10 sparing compared to Supra, which is important in inflammatory bowel syndrome ...
- Myelin Sheath Damage Mediated by Epigenetic Remedy in Multiple Sclerosis
“Small-molecule-induced epigenetic rejuvenation promotes SREBP condensation and overcomes barriers to CNS myelin regeneration.” According to the paper, the researchers treated mouse models of multiple ...
- Small molecule shows early-stage promise for repairing myelin sheath damage
When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate ...
- BridgeBio Spins Out Oncology Company with $200M in Financing
The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction between the RAS and PI3K pathways.
- BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class
BBOT began a phase 1 trial of KRAS G12C inhibitor BBO-8520 in non-small cell lung cancer last month. The start date of the study, which will test the molecule as a single agent and in combination with ...
Go deeper with Google Headlines on:
Small molecule inhibitors
[google_news title=”” keyword=”small molecule inhibitors” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
